What is Crystal Pharmatech?
Crystal Pharmatech operates as a technology-driven contract research organization (CRO) specializing in materials science and engineering for the pharmaceutical sector. Established in 2010, the company boasts R&D centers across Suzhou (China), New Jersey, San Francisco (USA), and Toronto (Canada). Its core strength lies in providing integrated and specialized services, encompassing API solid-state research, crystallization, preformulation, formulation development, and manufacturing for clinical supply. This comprehensive service offering positions Crystal Pharmatech as a key partner for drug developers seeking to optimize their compounds.
How much funding has Crystal Pharmatech raised?
Crystal Pharmatech has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2015): $10M with participation from Renren
Key Investors in Crystal Pharmatech
Renren
Renren, a Chinese internet company primarily focused on real estate and automobiles, participated in this strategic investment round, indicating a potential diversification of their investment portfolio into the life sciences sector.
What's next for Crystal Pharmatech?
The substantial enterprise-level investment Crystal Pharmatech has attracted signals a strong market confidence in its specialized approach to drug development. This capital infusion is expected to fuel further expansion of its R&D capabilities, enhance its service offerings, and potentially broaden its global reach. The company's focus on materials science and engineering for drug development positions it to capitalize on the increasing demand for efficient and innovative solutions in the pharmaceutical pipeline, likely leading to accelerated growth and strategic partnerships.
See full Crystal Pharmatech company page
